Accelerated corneal collagen cross-linking in paediatric keratoconus: long-term results and comparison of two protocols

Session Details

Session Title: Corneal Cross-Linking

Session Date/Time: Monday 16/09/2019 | 16:00-18:00

Paper Time: 16:24

Venue: South 5

First Author: : M.Sucu TURKEY

Co Author(s): :    Y. Yıldırım   B. Yıldız   A. Ağca                       

Abstract Details

Purpose:

To compare long term clinical results of two different accelerated corneal cross-linking (CXL) protocols in paediatric patients with keratoconus.

Setting:

Beyoglu Eye Training and Research Hospital, University of Health Science, ISTANBUL, TURKEY

Methods:

In this retrospective, case-control study, the medical files of patients with keratoconus who underwent two different accelerated CXL treatment (group 1; 30 mW/cm2 for 4 min and group 2; 18 mW/cm2 for 5 min) were evaluated. Patients who were <18 years of age and had at least 3-year follow-up were included. Thirty eyes of 24 patients comprised group 1, and 113 eyes of 74 patients comprised group 2. Preoperative and postoperative visual acuity (VA) and corneal topography parameters were assessed before and 1,3 and 5 years after surgery in both groups.

Results:

The mean age was 15.1±1.8 years and 14.4±2.2 years in group 1 and 2 respectively. The mean follow-up time was 4.44±0.92 years in group 1 and 4.07±1.0 years in group 2. There were no significant differences in any parameter between the groups preoperatively. In group 2, there was a statistically significant reduction in corneal pachymetry and total higher-order aberrations (HOAs). However, in group 1 none of the parameters including SimK, Kmax, pachymetry, HOAs, coma, trefoil and spherical aberration changed significantly during follow-up. There was only approximately 0.25D reduction in SimK and Kmax in both groups.

Conclusions:

Both accelerated protocols are beneficial in terms of halting keratoconus progression in pediatric patients. However, our results indicate a reduced effect of accelerated CXL on topographical parameters when compared with standard protocol.

Financial Disclosure:

None